FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912694021> ?p ?o ?g. }

• W2912694021 abstract "In patients undergoing autologous stem cell transplantation (aSCT), the recombinant human granulocyte colony-stimulating factor, filgrastim, has been historically utilized during mobilization. Filgrastim-SNDZ, a biosimilar of filgrastim, received landmark approval as the first biosimilar product approved by the FDA in the United States. Biosimilar products offer cost benefit over the reference product, while maintaining similar efficacy. As a result of the recent approval, our medical center made the conversion from using filgrastim to filgrastim-SNDZ as the preferred mobilizing agent to provide patients the same benefits at a reduced cost. The primary objective of this retrospective, observational cohort study was to assess the efficacy of filgrastim-SNDZ as a mobilizing agent in the SCT patient population compared to the formerly used reference product, filgrastim. The secondary objective was to confirm the cost savings associated with the conversion from filgrastim to filgrastim-SNDZ. Data was collected on two cohorts of patients undergoing mobilization prior to an aSCT who received either filgrastim or filgrastim-SNDZ. Efficacy was assessed based of the number of days of stem cell apheresis and number of CD34 stem cells collected during apheresis in both cohorts. Cost savings were assessed based on cost difference (average wholesale price) between the drug products. In total, 186 patients received an aSCT during this time frame. Sixty-nine patients were included in the filgrastim group and 78 were included in the filgrastim-SNDZ group. The difference in number of CD34 cells collected was not significant (p = 0.17). The median number of CD34 cells collected was 7.24 × 106 in the filgrastim group and 8.245 × 106 in the filgrastim-SNDZ group. The filgrastim-SNDZ group had a larger range of CD34 cells collected during apheresis than the filgrastim group. There was no statistically significant difference in number of CD34 cells collected between the groups in patients with multiple myeloma (p = 0.0969) or with non-Hodgkin's lymphoma (p = 0.976). Number of CD34 cells collected was also tested for non-inferiority with a non-inferiority margin of 0.73 (10%) and filgrastim-SNDZ was shown to be non-inferior in this outcome to filgrastim. The median number of days of apheresis was 2 in both groups and there was no significant difference in this outcome between the groups (p = 0.36). The cost comparison between groups showed significant cost savings with filgrastim-SNDZ. Annual cost savings is projected to be $92,000 for 93 patients receiving an average of 5 doses of filgrastim-SNDZ. This study shows that using filgrastim-SNDZ is an effective and cost savings option for mobilization prior to aSCT." @default.
• W2912694021 created "2019-02-21" @default.
• W2912694021 creator A5016063410 @default.
• W2912694021 creator A5072688860 @default.
• W2912694021 creator A5084489076 @default.
• W2912694021 creator A5089009114 @default.
• W2912694021 date "2019-03-01" @default.
• W2912694021 modified "2023-09-25" @default.
• W2912694021 title "Efficacy and Cost Savings Associated with a Conversion from Filgrastim to Filgrastim-Sndz in Stem Cell Transplant Patients Undergoing Mobilization" @default.
• W2912694021 doi "https://doi.org/10.1016/j.bbmt.2018.12.348" @default.
• W2912694021 hasPublicationYear "2019" @default.
• W2912694021 type Work @default.
• W2912694021 sameAs 2912694021 @default.
• W2912694021 citedByCount "0" @default.
• W2912694021 crossrefType "journal-article" @default.
• W2912694021 hasAuthorship W2912694021A5016063410 @default.
• W2912694021 hasAuthorship W2912694021A5072688860 @default.
• W2912694021 hasAuthorship W2912694021A5084489076 @default.
• W2912694021 hasAuthorship W2912694021A5089009114 @default.
• W2912694021 hasBestOaLocation W29126940211 @default.
• W2912694021 hasConcept C126322002 @default.
• W2912694021 hasConcept C141071460 @default.
• W2912694021 hasConcept C2776694085 @default.
• W2912694021 hasConcept C2776738589 @default.
• W2912694021 hasConcept C2777767877 @default.
• W2912694021 hasConcept C2779050716 @default.
• W2912694021 hasConcept C2779171977 @default.
• W2912694021 hasConcept C59491497 @default.
• W2912694021 hasConcept C71924100 @default.
• W2912694021 hasConcept C89560881 @default.
• W2912694021 hasConceptScore W2912694021C126322002 @default.
• W2912694021 hasConceptScore W2912694021C141071460 @default.
• W2912694021 hasConceptScore W2912694021C2776694085 @default.
• W2912694021 hasConceptScore W2912694021C2776738589 @default.
• W2912694021 hasConceptScore W2912694021C2777767877 @default.
• W2912694021 hasConceptScore W2912694021C2779050716 @default.
• W2912694021 hasConceptScore W2912694021C2779171977 @default.
• W2912694021 hasConceptScore W2912694021C59491497 @default.
• W2912694021 hasConceptScore W2912694021C71924100 @default.
• W2912694021 hasConceptScore W2912694021C89560881 @default.
• W2912694021 hasLocation W29126940211 @default.
• W2912694021 hasOpenAccess W2912694021 @default.
• W2912694021 hasPrimaryLocation W29126940211 @default.
• W2912694021 hasRelatedWork W1805125689 @default.
• W2912694021 hasRelatedWork W2002161714 @default.
• W2912694021 hasRelatedWork W2022427990 @default.
• W2912694021 hasRelatedWork W2030281591 @default.
• W2912694021 hasRelatedWork W2099428271 @default.
• W2912694021 hasRelatedWork W2589409330 @default.
• W2912694021 hasRelatedWork W2972351380 @default.
• W2912694021 hasRelatedWork W3176989103 @default.
• W2912694021 hasRelatedWork W3198647362 @default.
• W2912694021 hasRelatedWork W2557064236 @default.
• W2912694021 isParatext "false" @default.
• W2912694021 isRetracted "false" @default.
• W2912694021 magId "2912694021" @default.
• W2912694021 workType "article" @default.